|
Population pharmacokinetics (Pop PK) of MYL-1402O (a proposed biosimilar to bevacizumab) and reference product (Avastin) in patients with nonsquamous non-small cell lung cancer (nsNSCLC). |
|
|
Employment - Cognigen Corporation |
Leadership - Cognigen Corporation |
Stock and Other Ownership Interests - Cognigen Corporation |
Consulting or Advisory Role - Mylan |
|
|
|
Stock and Other Ownership Interests - Viatris |
Research Funding - Viatris |
Patents, Royalties, Other Intellectual Property - Viatris |
Expert Testimony - Viatris |
Travel, Accommodations, Expenses - Viatris |
|
|
|
Stock and Other Ownership Interests - Viatris |
Patents, Royalties, Other Intellectual Property - Viatris |
|
|
Employment - Cognigen Corporation |
Stock and Other Ownership Interests - Cognigen Corporation |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Viatris |
|
|
No Relationships to Disclose |
|
Sundara Moorthi Nainar Murugesan |
|
|
Ashwini Vishweswaramurthy |
|
|
|
|
Stock and Other Ownership Interests - Biocon |
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Viatris |
|
|
Consulting or Advisory Role - Alvotech; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai/Roche; Lilly; MSD; Mylan; Pfizer; Roche; Takeda |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; IPSEN |
|
|
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Genentech; Guardant Health; Lilly; Merck; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca/MedImmune; Genentech; Janssen; Lilly; Novartis |
Speakers' Bureau - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Merck |
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Spectrum Pharmaceuticals (Inst) |